- Conditions
- HIV Prevention
- Interventions
- emtricitabine 200mg/tenofovir 300mg
- Drug
- Lead sponsor
- University of California, Los Angeles
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 328 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2016
- U.S. locations
- 2
- States / cities
- Los Angeles, California
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–48
of 518
matching trials from the live ClinicalTrials.gov search.
- Conditions
- HIV, HIV Infections
- Interventions
- E/C/F/TAF, E/C/F/TDF, E/C/F/TDF Placebo, E/C/F/TAF Placebo
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 872 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2017
- U.S. locations
- 78
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 55 more
- Conditions
- HIV Infections
- Interventions
- Not listed
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 56 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2009
- U.S. locations
- 1
- States / cities
- Cleveland, Ohio
- Conditions
- Chronic HBV Infection
- Interventions
- GS-4774, OAV Regimen
- Biological · Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 178 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2015
- U.S. locations
- 16
- States / cities
- Los Angeles, California • Pasadena, California • Sacramento, California + 13 more
- Conditions
- HIV Infections
- Interventions
- Subjects do not receive study medication in this study 202094
- Drug
- Lead sponsor
- ViiV Healthcare
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 102 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2018
- U.S. locations
- 7
- States / cities
- Los Angeles, California • San Francisco, California • Washington D.C., District of Columbia + 4 more
- Conditions
- HIV Infection
- Interventions
- efavirenz, tenofovir, abacavir/lamivudine
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 345 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2004
- U.S. locations
- 58
- States / cities
- Phoenix, Arizona • Fountain Valley, California • Los Angeles, California + 42 more
- Conditions
- Chronic Hepatitis B
- Interventions
- Tenofovir disoproxil fumarate
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 90 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2010
- U.S. locations
- 21
- States / cities
- Fountain Valley, California • Hacienda Heights, California • Los Angeles, California + 17 more
- Conditions
- Chronic Hepatitis B
- Interventions
- TDF, ADV, TDF placebo, ADV placebo, FTC/TDF
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years to 69 Years
- Enrollment
- 382 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2016
- U.S. locations
- 17
- States / cities
- La Jolla, California • Pasadena, California • San Diego, California + 12 more
- Conditions
- Healthy Adult Females
- Interventions
- Pharmacokinetic Sampling
- Other
- Lead sponsor
- University of North Carolina, Chapel Hill
- Other
- Eligibility
- 18 Years to 49 Years · Female only
- Enrollment
- 49 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2012 – 2013
- U.S. locations
- 1
- States / cities
- Chapel Hill, North Carolina
- Conditions
- Chronic Hepatitis B
- Interventions
- Entecavir + Tenofovir, Adefovir + continuing Lamivudine
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 4 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2009
- U.S. locations
- 4
- States / cities
- Los Angeles, California • San Francisco, California • Chicago, Illinois + 1 more
- Conditions
- HIV
- Interventions
- Truvada, Raltegravir
- Drug
- Lead sponsor
- The University of Texas Health Science Center, Houston
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 103 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2015
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Healthy
- Interventions
- Darunavir (DRV), Cobicistat (COBI), Emtricitabine (FTC), Tenofovir Alafenamide (TAF)
- Drug
- Lead sponsor
- Janssen Scientific Affairs, LLC
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016 – 2017
- U.S. locations
- 1
- States / cities
- Tempe, Arizona
- Conditions
- HIV Infections
- Interventions
- ARV regimen chosen by treating physician
- Drug
- Lead sponsor
- Kristine Patterson, MD
- Other
- Eligibility
- 19 Years and older · Female only
- Enrollment
- 11 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2012
- U.S. locations
- 1
- States / cities
- Chapel Hill, North Carolina
- Conditions
- HIV Prevention
- Interventions
- Text Messaging, Adherence Counseling, Daily Oral PrEP
- Behavioral · Drug
- Lead sponsor
- University of California, Los Angeles
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 136 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2019
- U.S. locations
- 5
- States / cities
- Los Angeles, California • San Diego, California
- Conditions
- HIV
- Interventions
- FTC/TAF
- Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 14 Years to 100 Years
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2016
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- HIV-1 Infection
- Interventions
- B/F/TAF, NRTIs, Third Agent
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 496 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2020
- U.S. locations
- 82
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Los Angeles, California + 53 more
- Conditions
- HIV Pre-exposure Prophylaxis, PrEP
- Interventions
- PrEP Uptake with Rapid Start, Pre-Exposure Prophylaxis (PrEP) Persistence
- Behavioral
- Lead sponsor
- University of Texas Southwestern Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 250 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026 – 2028
- U.S. locations
- 1
- States / cities
- Dallas, Texas
- Conditions
- Hepatitis B
- Interventions
- Tenofovir, Peginterferon-alfa 2a and tenofovir
- Drug
- Lead sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 201 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2021
- U.S. locations
- 20
- States / cities
- Los Angeles, California • San Francisco, California • Honolulu, Hawaii + 11 more
- Conditions
- HIV Infections
- Interventions
- Cabotegravir Oral Tablet, TDF/FTC tablets, Placebo for TDF/FTC tablets, Placebo for cabotegravir oral tablet, CAB LA, Placebo for CAB LA
- Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 4,570 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016 – 2025
- U.S. locations
- 27
- States / cities
- Birmingham, Alabama • Los Angeles, California • Oakland, California + 20 more
- Conditions
- Human Immunodeficiency Virus Type 1 (HIV-1) Infection
- Interventions
- ISL, ULO, BIC/FTC/TAF
- Drug
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 150 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2031
- U.S. locations
- 11
- States / cities
- San Francisco, California • West Hollywood, California • Washington D.C., District of Columbia + 8 more
- Conditions
- HIV Infections
- Interventions
- FTC 200 mg/TDF 300 mg fixed-dose combination tablet
- Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 557 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2012 – 2015
- U.S. locations
- 3
- States / cities
- San Francisco, California • Washington D.C., District of Columbia • Miami, Florida
- Conditions
- HIV Infections
- Interventions
- Tenofovir 1% vaginal gel
- Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 45 Years · Female only
- Enrollment
- 21 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- Ends 2010
- U.S. locations
- 1
- States / cities
- Pittsburgh, Pennsylvania
- Conditions
- Risk Reduction
- Interventions
- Motivational Interviewing Counselling, Point-of-care Urine Tenofovir Measurement
- Behavioral · Device
- Lead sponsor
- University of California, San Francisco
- Other
- Eligibility
- 18 Years to 30 Years · Male only
- Enrollment
- 63 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2025
- U.S. locations
- 1
- States / cities
- San Francisco, California
- Conditions
- HIV
- Interventions
- Biktarvy
- Drug
- Lead sponsor
- Brigham and Women's Hospital
- Other
- Eligibility
- 18 Years to 95 Years
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2021
- U.S. locations
- 3
- States / cities
- Boston, Massachusetts